This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Clinical Question
How does Selank function as a synthetic tuftsin analog, and what is the current clinical evidence regarding its modulation of the GABAergic system and its regulatory status in the United States?
Evidence Snapshot
- Compound Type: Synthetic tuftsin analog (heptapeptide).
- Evidence Grade: B-.
- Primary Mechanism: GABA-A receptor system modulation and normalization of serotonin/dopamine receptors.
- Key Outcomes: Comparable effects to benzodiazepines without associated sedation, tolerance, or dependence; fMRI evidence of activity.
- Regulatory Status: Approved in Russia; not FDA-approved. Removed from FDA Category 2 compounding list following nomination withdrawal.
What the Research Shows
Selank is a synthetic heptapeptide derived from the endogenous tetrapeptide tuftsin. Clinical data, largely originating from Russian clinical practice, suggests the compound acts as an anxiolytic agent. Functional MRI (fMRI) studies have provided evidence of its activity within the central nervous system.
Research indicates that the clinical effects of Selank are comparable to those of benzodiazepines. However, the data distinguishes Selank by the absence of typical benzodiazepine side effects, specifically noting a lack of sedation, tolerance development, or physical dependence. Beyond its neurological applications, the research also highlights immunomodulatory effects, including the induction of interferon and demonstrated antiviral activity against influenza.
Mechanism
Based on provided mechanism data, Selank operates through several distinct pathways:
- GABA-A Modulation: It modulates the GABA-A receptor system, a mechanism similar to benzodiazepines, though it does not produce the sedative or dependency-related outcomes associated with that class of drugs.
- Neurotransmitter Normalization: The peptide acts to normalize serotonin and dopamine receptor activity.
- Neurotrophic Support: Selank has been shown to enhance the expression of Brain-Derived Neurotrophic Factor (BDNF).
- Immunomodulation: It serves as an immunomodulator, inducing interferon and providing antiviral activity against influenza.
Limitations of the Evidence
The primary limitation of the current evidence base is its geographic concentration; most clinical data is derived from Russian clinical practice. There is currently limited independent Western replication of these findings. Furthermore, because Selank is often administered via nasal spray, questions remain regarding its bioavailability and consistent delivery to the central nervous system.
From a regulatory standpoint, the FDA has raised significant concerns. These include issues involving peptide characterization, immunogenicity, the potential for aggregation, and the presence of peptide-related impurities. There is also a noted lack of comprehensive safety information in the Western clinical record.
Regulatory Status
Selank is not FDA-approved for any indication in the United States. While it was placed in FDA Category 2 under the interim 503A nomination policy in September 2023, the nomination was subsequently withdrawn in September 2024, and it was removed from Category 2. It is not listed under 503B. The FDA issued a warning letter to Tailor Made in 2020 regarding this compound. Internationally, Selank maintains approved status in Russia.
Clinical Takeaway
Selank represents a Grade B- evidence-based peptide that modulates the GABA-A system and BDNF expression without the sedation or dependence characteristic of benzodiazepines. However, the lack of Western replication and the FDA’s concerns regarding immunogenicity and impurities suggest a need for cautious interpretation of available data. Physicians should note that the regulatory environment for this compound has shifted following its removal from the FDA Category 2 list.
For practitioners interested in evaluating emerging peptide literature, you may find a doctor through our directory to discuss the current regulatory landscape. A qualified peptide doctor can provide further context on how international clinical data compares to domestic safety standards. The cost of such consultations and any associated clinical monitoring will vary by prescriber and location.
Sources
- TruthTides Peptide Database: Selank Clinical Grade and Mechanism Profile.
- FDA: Certain bulk drug substances that may present significant safety risks (Review date: September 27, 2026).
- FDA: Bulk drug substances used in compounding (Status update: September 2024).
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.